JENA, Germany--(BUSINESS WIRE)--InflaRx GmbH, announced today the closing of its seed financing led by Affentranger Associates alongside with bm-t beteiligungsmanagement thüringen gmbh. InflaRx’s mission is to develop new therapeutic approaches to prevent and treat sepsis. Created by Prof. Niels Riedemann and Prof Renfeng Guo, two worldwide recognized researchers in the field of inflammation and sepsis, InflaRx has already brought its leading development program targeting activation products of the complement system in an advanced pre-clinical stage.
